Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 9Head & Neck 6Gastrointestinal 5Thoracic 4CNS 4Lymphoid 3Other hematologic neoplasm 2Gynecologic 2Breast 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Pancreatic Neuroendocrine Tumors (pNET) 1

Interventions

lutetium Lu 177 dotatate 13Specimen Handling 8Magnetic Resonance Spectroscopy 8Everolimus 8cabozantinib 6pembrolizumab 5Nivolumab 4olaparib 3lenvatinib 3X-Rays 3Lutetium-177 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2avelumab 2amino-acid, glucose, and electrolyte solution 2Sunitinib 2Radiotherapy 2Phantoms, Imaging 2Octreotide 2Ipilimumab 2Fluorodeoxyglucose F18 2Etoposide 2Cyclophosphamide 2Cisplatin 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2telotristat ethyl 1surufatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Watchful Waiting × NET × 90 days × Clear all
NCT07591493 2026-05-15

ADJUPANET

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Not yet recruiting
300 enrolled
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors (pNET)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡